SCHEMBL3923359

SCHEMBL3923359

OC(CCCl)c1cccc2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
ALDH1A1 P00352 2/20 0.47
TSHR P16473 2/20 0.43
ADRA2A P08913 2/20 0.41
ADRA2B P18089 2/20 0.41
ADRA2C P18825 2/20 0.41
ADRA1D P25100 2/20 0.41
ADRA1A P35348 2/20 0.41
ADRA1B P35368 2/20 0.41
SLC6A4 P31645 1/20 0.41
ACP3 P15309 4/20 0.41
KMT2A Q03164 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
METAP2 P50579 1/20 0.39
METAP1 P53582 1/20 0.39
CYP2A6 P11509 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3923362 1.00 CYP1A2 (0.47) CYP1A2CYP2C9CYP2C19ALDH1A1TSHR
SCHEMBL3919019 0.85 CYP1A2 (0.50) CYP1A2CYP2C9CYP2C19ALDH1A1TSHR
SCHEMBL3919021 0.85 CYP1A2 (0.50) CYP1A2CYP2C9CYP2C19ALDH1A1TSHR
SCHEMBL27991615 0.83 CYP2C19 (0.48) CYP1A2CYP2C9CYP2C19ALDH1A1TSHR
SCHEMBL2734713 0.81 ALDH1A1 (0.47) CYP1A2CYP2C9CYP2C19ALDH1A1TSHR
SCHEMBL5384063 0.81 ALDH1A1 (0.47) CYP1A2CYP2C9CYP2C19ALDH1A1TSHR
SCHEMBL8375544 0.81 CYP2C9 (0.47) CYP1A2CYP2C9CYP2C19ALDH1A1TSHR
SCHEMBL4949690 0.81 CYP2C9 (0.47) CYP1A2CYP2C9CYP2C19ALDH1A1TSHR
SCHEMBL15171136 0.81 ALDH1A1 (0.47) CYP1A2CYP2C9CYP2C19ALDH1A1TSHR
SCHEMBL6313224 0.80 TSHR (0.46) CYP1A2CYP2C9CYP2C19ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1934159-B1 METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS BASF SE (DE) 2009-03-25 EP disclosed
US-20090030235-A1 METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS BASF SE (DE) 2009-01-29 US disclosed
EP-1934159-A1 METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS BASF SE (DE) 2008-06-25 EP disclosed
WO-2007036570-A1 METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS BASF AKTIENGESELLSCHAFT (DE) 2007-04-05 WO disclosed
EP-1505156-B1 Process for the enantioselective preparation of secondary alcohols by lipase catalysed solvolysis of the corresponding acetoacetic acid ester CONSORTIUM ELEKTROCHEM IND (DE) 2005-12-07 EP disclosed
US-20050032182-A1 Process for the enantioselective preparation of secondary alcohols by lipase-catalyzed solvolysis of the corresponding acetoacetic esters CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH 2005-02-10 US disclosed
EP-1505156-A1 Process for the enantioselective preparation of secondary alcohols by lipase catalysed solvolysis of the corresponding acetoacetic acid ester Consortium für elektrochemische Industrie GmbH (DE) 2005-02-09 EP disclosed
US-6365398-B1 REACTING RACEMIC CARBOXYLIC ACID ESTER WITH RACEMIC ALCOHOL IN PRESENCE OF A CARBOXYL ESTER HYDROLASE BASF AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed
EP-1031629-A2 Method of preparation of stereoisomeric carboxylic acid esters BASF AKTIENGESELLSCHAFT (DE) 2000-08-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030235-A1 METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS ADH5, ADH1C, ADH1A CYP1A2 65/4885CYP2C9 280/4885CYP2C19 607/4885
US-20050032182-A1 Process for the enantioselective preparation of secondary alcohols by lipase-catalyzed solvolysis of the corresponding acetoacetic esters LIPC, LIPE, LIPA CYP1A2 453/4885CYP2C9 1370/4885CYP2C19 1732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.